Shares of Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) rose 2% during trading on Wednesday . The stock traded as high as $1.53 and last traded at $1.53. Approximately 292,991 shares were traded during trading, a decline of 21% from the average daily volume of 368,852 shares. The stock had previously closed at $1.50.
Wall Street Analysts Forecast Growth
Separately, Canaccord Genuity Group initiated coverage on shares of Fractyl Health in a research report on Tuesday, April 15th. They set a "buy" rating and a $12.00 price objective on the stock.
Read Our Latest Report on GUTS
Fractyl Health Stock Up 2.0%
The stock has a market capitalization of $74.94 million, a P/E ratio of -0.83 and a beta of 1.58. The company's 50-day moving average price is $1.81 and its 200 day moving average price is $1.62. The company has a debt-to-equity ratio of 4.61, a quick ratio of 2.50 and a current ratio of 2.50.
Fractyl Health (NASDAQ:GUTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.49) EPS for the quarter, meeting the consensus estimate of ($0.49). Fractyl Health had a negative net margin of 73,864.52% and a negative return on equity of 228.66%. As a group, equities analysts expect that Fractyl Health, Inc. will post -1.61 earnings per share for the current year.
Hedge Funds Weigh In On Fractyl Health
Several institutional investors have recently bought and sold shares of GUTS. Rhumbline Advisers grew its stake in Fractyl Health by 73.1% during the fourth quarter. Rhumbline Advisers now owns 25,626 shares of the company's stock valued at $53,000 after acquiring an additional 10,826 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Fractyl Health by 27.3% in the 4th quarter. Bank of New York Mellon Corp now owns 41,448 shares of the company's stock worth $85,000 after buying an additional 8,886 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Fractyl Health in the 4th quarter worth $34,000. HighTower Advisors LLC grew its stake in shares of Fractyl Health by 72.8% in the 4th quarter. HighTower Advisors LLC now owns 25,921 shares of the company's stock worth $53,000 after buying an additional 10,921 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of Fractyl Health in the 4th quarter worth $34,000.
Fractyl Health Company Profile
(
Get Free Report)
Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fractyl Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fractyl Health wasn't on the list.
While Fractyl Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
